Published online Jun 14, 2023. doi: 10.3748/wjg.v29.i22.3422
Peer-review started: February 15, 2023
First decision: March 28, 2023
Revised: April 10, 2023
Accepted: May 11, 2023
Article in press: May 11, 2023
Published online: June 14, 2023
Liver fibrosis is a pathological change caused by chronic liver injury, and is a key link in the progression of chronic liver diseases to cirrhosis or liver cancer. How to prevent and reverse liver fibrosis is currently a hot and difficult research topic, and fully understanding and elucidating the pathogenesis of liver fibrosis is the foundation of prevention and treatment. At present, there is still a lack of safe and effective treatment for liver cirrhosis clinically. It is of great significance to deeply study the pathogenesis of liver fiber and prevent and treat it in order to reduce the incidence rate and mortality of liver cirrhosis.
Studies have shown that liver fibrosis is closely related to inflammation in chronic liver disease, and annexin (Anx)A1 has strong anti-inflammatory effects. Therefore, this study focuses on the pathogenesis of liver fibrosis and investigates the role of AnxA1 in liver fibrosis. Provide valuable information for antifibrosis therapy.
To investigate molecular and cellular mechanisms of liver fibrosis and evaluate the effect of AnxA1 in hepatic fibrosis.
Biomarkers as drug development tools, biomarker discovery and validation using a combination of in vitro and in vivo studies. A large and wide range of animal models and cell experiments can be used, and experiments can be repeated multiple times.
AnxA1/formylpeptide receptor (FPR) inhibits the activation of hepatic stellate cells by regulating macrophage function through the Wnt/β-catenin pathway in the CCl4-induced hepatic fibrosis mice.
AnxA1 may involve in the pathogenesis of liver fibrosis and as a potential therapeutic target.
This study investigates the mechanism of Anxa1 in liver fibrosis by using wild mice/Anxa1 knockout mice in combination with Anxa1 mimetic peptide and FPR receptor inhibitor to provide an experimental basis for the possible use of Anxa1 in the treatment of liver fibrosis.